Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference | Nation / World

NEW YORK – (BUSINESS WIRE) – December 30, 2021–

Pfizer Inc. (NYSE: PFE) Invites Investors and the General Public to Listen to a Webcast of a Discussion with Albert Bourla, President and CEO, at the 14th Annual Goldman Healthcare CEOs Conference Sachs, Thursday January 6, 2022 at 10 a.m. : 00 Eastern Standard Time.

To view and listen to the webcast, visit our website at Information on accessing and registering for the webcast will be available at starting today.

The transcript and webcast of the discussion will be available on our website at within 24 hours of the end of the live chat and will be accessible for at least 90 days.

About Pfizer: Advances That Change Patients’ Lives

At Pfizer, we apply science and our global resources to provide people with therapies that extend and dramatically improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health products, including innovative drugs and vaccines. Every day, Pfizer colleagues work in developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. In line with our responsibility as one of the world’s leading innovative biopharmaceutical companies, we collaborate with healthcare providers, governments and local communities to support and expand access to reliable and affordable healthcare in the whole world. For more than 170 years, we’ve worked to make a difference for all those who rely on us. We regularly post information that may be important to investors on our website at In addition, to find out more, visit us on and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, Youtube and like us on Facebook at

Disclosure Notice:Webcasting may include forward-looking statements regarding, among other things, our anticipated operational and financial performance, reorganizations, business plans and prospects; expectations regarding our product portfolio, in-line products and product candidates, including planned regulatory submissions, data readings, study starts, approvals, clinical trial results and other data in development , contribution to revenue, growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; dividends and share buybacks; the plans and outlook for our acquisitions, divestitures and other business development activities, and our ability to successfully capitalize on these opportunities; manufacture and supply of products; and our efforts to respond to COVID-19, including our development of a vaccine to help prevent COVID-19 and the treatment of COVID-19, which are subject to substantial risks and uncertainties that could cause actual results differ materially from those expressed or implied by such statements. A description of these risks and uncertainties can be found in Pfizer’s annual report on Form 10-K for the year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including sections thereof. entitled “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the United States Securities and Exchange Commission and available at the ‘address and

Forward-looking statements of the webcast speak only as of the original date of the webcast. Pfizer assumes no obligation to update any forward-looking statements contained in the webcast as a result of new information or future events or developments.

View source version on


[email protected]

+1 (212) 733-1226 Investors:

[email protected]

+1 (212) 733-4848



SOURCE: Pfizer Inc.

Copyright Business Wire 2021.

PUB: 12/30/2021 10 a.m. / DISC: 12/30/2021 10:02 a.m.

Copyright Business Wire 2021.